有效的预后风险模型与喉癌中与cuproptosis相关的基因
Cong Li1, Yongzhi Zhu2, Song Shi1
1Shanghai Jiao Tong University School of Medicine, Tongren Hospital, Department of Otorhinolaryngology, Shanghai, China.
Brazilian journal of otorhinolaryngology
|January 16, 2024
概括
与cuproptosis相关的基因显示为喉癌的预后标记物,有助于风险分层和识别潜在的治疗点,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 喉癌的复发率很高,有效的生物标志物缺乏.
- 细胞亡是一种受调节的细胞死亡途径,与癌症的进展有关.
- 了解与cuproptosis相关的基因对于喉癌的治疗至关重要.
研究的目的:
- 为了研究 cuproptosis 相关基因在喉癌中的作用.
- 在这些基因内识别预后标记物和潜在的治疗标.
- 开发一个预测性模型来预测喉癌患者的结果.
主要方法:
- 利用癌症基因组图谱和基因表达总汇数据库来获得全面的数据.
- 采用聚类和基因分析来识别预后性cuproptosis相关的基因.
- 构建了一个风险模型和名图,通过单变量/多变量分析和基因组丰富分析进行验证.
主要成果:
- 一个四基因风险模型 (包括跨膜2,β-catenin1,statmin2和G蛋白结合受体173的脱节结合对手) 显著差异化了患者的结局.
- 确定了独立的预后因素,并整合到预测性名ogram中.
- 基因组丰富分析揭示了与高风险患者组相关的独特途径.
结论:
- 与cuproptosis相关的基因在喉癌中作为有价值的预后指标.
- 这些基因代表了治疗喉癌治疗的有希望的治疗标.
- 这项研究为了解和管理喉癌开辟了新的途径.
相关概念视频
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353


